E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult patients with Atypical Hemolytic Uremic Syndrome (aHUS) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019515 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assess the efficacy of eculizumab in adult patients with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal impairment. |
|
E.2.2 | Secondary objectives of the trial |
Characterize the overall safety and tolerability of eculizumab in this population. - Evaluate the efficacy of eculizumab by additional efficacy measures : Duration of complete TMA response. Time to complete TMA response. Complete hematologic response. Renal function measures. Control of hemolysis with improvement of hemoglobin. Plasma Therapy event-free status. New Dialysis event-free status. Quality of Life (QoL) measures. Exploratory objective : Evaluate potential inprovement in levels of pro-thrombotic, pro-inflammatory and complement markers |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patient must be willing and able to give written informed consent. 2. Patient’s age ≥ 18 years. 3. Platelet count at screening must be < lower limit of normal range (LLN) 4. Signs or symptoms of hemolysis (i.e, LDH≥1.5 � upper limit or normal range (ULN) and hemoglobin ≤ LLN) at start of current aHUS event. 5. Serum Creatinine (SrCr) level ≥ ULN (patients requiring dialysis for acute renal failure are also eligible). 6. Patients with diagnosis of aHUS with or without an identified complement regulatory protein genetic abnormality or anti-complement factor antibody and for whom known etiologies of hemolytic uremic syndrome (HUS) have been ruled out as confirmed in the Exclusion Criteria. 7. Female patients of childbearing potential must be practicing an effective, reliable and medically approved contraceptive regimen during the entire duration of the study, including the follow-up period. At the time of the last follow-up visit, patients must agree to continue to use adequate contraception methods for up to 5 months following discontinuation of eculizumab treatment. 8. Able and willing to comply with study procedures |
|
E.4 | Principal exclusion criteria |
1. Known familial ADAMTS-13 deficiency (ADAMTS-13<5%) 2. Typical HUS (known Shiga toxin +). 3. History of malignancy within 5 years of screening. 4. Known human immunodeficiency virus (HIV) infection. 5. Identified drug exposure-related HUS. 6. Infection-related HUS. 7. HUS related to bone marrow transplant (BMT). 8. HUS related to vitamin B12 deficiency. 9. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome. 10. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for end-stage renal disease). 11. Patients with a confirmed diagnosis of sepsis defined as positive blood cultures within 7 days of the screening visit and not treated with antibiotics to which the organism is sensitive. 12. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease. 13. Pregnancy or lactation. 14. Unresolved systemic meningococcal disease. 15. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient’s risk by participating in the study or confound the outcome of the study. 16. Patients receiving chronic intravenous immunoglobulin (IVIg) within 8 weeks (e.g., hypogammaglobinemia). or chronic rituximab therapy within 12 weeks of the screening visit unless for unrelated medical condition 17. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors, calcineurin inhibitors (e.g., cyclosporine or tacrolimus) are excluded unless: [1] part of an established post-transplant anti-rejection regime, or [2] patient has confirmed anti-Complement Factor Antibodies requiring immunosuppressive therapy or [3] steroids are being used for a condition other than aHUS (example asthma). 18. Participation in any other investigational drug trial or device trial, or procedures beginning 4 weeks prior to screening and throughout the entire trial. 19. Prior eculizumab use, hypersensitivity to eculizumab, to murine proteins or to one of the excipients |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients with complete TMA response as evidenced by normalization of hematological parameters [platelet count and lactate deshydrogenase (LDH)] and preservation of renal function (no increase in serum creatinine from baseline) during treatment with eculizumab |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 31 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Ultima visita ultimo paziente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |